@article{oai:niigata-u.repo.nii.ac.jp:00018240,
 author = {末山, 博男 and 酒井, 邦夫 and 杉田, 公 and 伊藤, 猛 and 土田, 恵美子 and 益子, 典子},
 issue = {2},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Feb},
 note = {In Europe and North America, approximately 60～70% of patients with all stages Hodgkin' s disease (HD) can be cured with treatment by radiotherapy alone, chemotherapy alone, or combined modality therapy (CMT). In early-stage HD, a 10-year relapse free rate of 70～80% and 10-year survival rate of 90～95% have been achieved by radiation thepapy alone. However, a number of clinical factors impacting on relapse free survival rate have been identified among the patients with early-stage HD. The most commonly recognized poor prognostic factor in those patients is the bulky mediastinal mass. Many investigators have pointed out that patients with early-stage bulky mediastinal disease have a high relapse rate when treated with radiotherapy alone. The vast majority of treatment failure site were intrathoracic. Therfore, many authors now recommend CMT. But there are so many controversial issues such as significance of staging laparotomy, the optimal chemotherapy combination, the number of cycles of chemotherapy, the sequence of treatments, and the extent of irradiation field in CMT that the optimal treatment for bulky mediastinal HD has not been established. Then we discussod the management strategies for early-stage HD with bulky mediastinal mass by reviewing the English language medical literatures published in western coutries in which clinical and pathological studies on HD had been progressing vigorously.},
 pages = {63--71},
 title = {巨大縦隔腫瘤を伴う早期Hodgkin病の治療},
 volume = {110},
 year = {1996}
}